ars-pharma.comHealthcareFounded: 2015Funding to Date: $76.55MM
ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.
For more details on financing and valuation for ARS Pharmaceuticals, register or login.
View Enterprise Value for ARS Pharmaceuticals.
To read this article and more news on ARS Pharmaceuticals, register or login.